Nitrofurantoin Aurobindo (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA, proteins and cell‑wall synthesis, resulting in a bactericidal effect that is concentrated in the urine where the infection resides.

The prescribed dose of Nitrofurantoin Aurobindo is determined by the treating clinician based on the patient’s condition, renal function and local prescribing guidelines. Patients should follow the prescriber’s instructions exactly.

Nitrofurantoin is classified as pregnancy category B, indicating that it may be used when the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk in small amounts; breastfeeding decisions should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with agents such as trimethoprim‑sulfamethoxazole, nitrofurantoin achieves high urinary concentrations with limited systemic exposure, making it effective for lower‑tract infections while having a distinct resistance profile. Choice of therapy depends on local susceptibility patterns and patient factors.

Nitrofurantoin Aurobindo tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, heat and direct sunlight to maintain potency.

The medication is taken orally, usually with food or a full glass of water to reduce gastrointestinal irritation. The exact dosing schedule—such as once or twice daily—must be prescribed by a qualified healthcare professional.

Serious adverse events include pulmonary toxicity (interstitial pneumonitis or fibrosis), severe hepatic injury, hemolytic anemia in patients with G6PD deficiency, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin, or G6PD deficiency should avoid this medication. Clinicians should also exercise caution in pregnant women, the elderly and those with a history of pulmonary disease.